drugset / Trial / NCT04862234
Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
Phase 4
Terminated
16 enrolled
Emory University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Hyperglycemia is seen in approximately 30% of patients who do not have a history of diabetes and undergo general surgery. Hyperglycemia in this setting is associated with increased risk of postoperative complications. The purpose of this study is to investigate risk factors for developing high sugars during the time of surgery, and if these high sugars can be prevented by the use of an injectable diabetes medication (dulaglutide) prior to surgery.
Timeline
- Start
- 2021-08-06
- Primary completion
- 2023-06-22
- Completion
- 2023-06-22
Outcome
Outcome not reported
Stopped: “This clinical trial was terminated on June 7, 2024 due to new information about contraindications of using the study drug in this population.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |